Last 44 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 227.94 | 67.05 | — | 3.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 5.23 | 4.72 | 3.96 | 1.55 | 3.06 | 4.11 | 4.65 | 4.54 | 5.95 | 10.49 | 12.39 | 10.36 | 28.61 | 41.87 | 63.11 | 84.48 | 73.85 | 86.62 | 16.79 | 124.93 | 2045.48 |
| — | +14.9% | -14.9% | -65.7% | -48.7% | -60.8% | -62.5% | -56.2% | -79.2% | -75.0% | -80.4% | -87.7% | -61.3% | -51.7% | +275.8% | -32.4% | -96.4% | — | +270.6% | -85.9% | — | |
| P/B Ratio | 13.97 | 12.22 | 8.55 | 7.11 | 13.96 | 16.71 | 17.30 | 15.07 | 17.98 | 27.10 | 37.31 | 19.70 | 31.47 | 18.23 | 33.68 | 24.25 | 14.42 | 10.78 | 20.39 | — | — |
| — | -26.9% | -50.6% | -52.8% | -22.4% | -38.4% | -53.6% | -23.5% | -42.9% | +48.7% | +10.8% | -18.7% | +118.3% | +69.1% | +65.2% | — | — | -83.6% | -8.0% | — | — | |
| P/FCF | 116.69 | — | — | 6.58 | 124.06 | — | 51.11 | 26.20 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | -74.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 92.50 | 48.01 | — | 3.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 95.10 | 43.60 | — | 3.13 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.8% | 84.8% | 85.1% | 94.7% | 92.1% | 79.4% | 80.8% | 83.0% | 88.2% | 88.0% | 86.4% | 79.7% | 91.2% | 82.6% | 87.1% | 93.7% | 99.5% | 91.3% | 99.3% | 97.4% | 100.0% |
| — | +6.8% | +5.4% | +14.1% | +4.4% | -9.8% | -6.5% | +4.1% | -3.3% | +6.6% | -0.8% | -15.0% | -8.4% | -9.6% | -12.3% | -3.7% | -0.5% | — | -0.6% | -2.6% | — | |
| Operating Margin | 5.5% | 9.9% | -25.6% | 48.7% | -18.6% | -50.0% | -12.3% | -24.0% | -14.7% | -36.0% | -57.7% | -124.2% | -126.8% | -390.4% | -723.9% | -693.4% | -910.6% | -897.0% | -148.3% | -2265.4% | -31185.7% |
| — | +119.7% | -107.8% | +302.6% | -26.5% | -38.7% | +78.7% | +80.7% | +88.4% | +90.8% | +92.0% | +82.1% | +86.1% | +56.5% | -388.2% | +69.4% | +97.1% | — | -384.9% | +88.7% | — | |
| Net Margin | 2.2% | 7.0% | -29.5% | 47.0% | -23.6% | -55.3% | -17.1% | -29.2% | -18.9% | -38.5% | -60.5% | -127.0% | -128.5% | -396.4% | -732.4% | -867.2% | -955.6% | -966.1% | -245.4% | -3461.4% | -35183.1% |
| — | +112.6% | -72.4% | +261.2% | -25.2% | -43.4% | +71.7% | +77.0% | +85.3% | +90.3% | +91.7% | +85.4% | +86.6% | +59.0% | -198.5% | +74.9% | +97.3% | — | -883.8% | +83.5% | — |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.5% | 4.8% | -15.3% | 77.4% | -26.3% | -47.0% | -15.6% | -22.9% | -14.2% | -28.8% | -41.5% | -48.6% | -32.2% | -61.1% | -69.6% | -59.6% | -39.2% | -42.0% | -209.3% | — | — |
| — | +110.1% | +2.1% | +437.8% | -85.4% | -63.0% | +62.4% | +52.8% | +56.0% | +52.9% | +40.3% | +18.5% | +17.7% | -45.3% | +66.8% | — | — | +70.7% | -515.1% | — | — | |
| ROA | 2.3% | 1.7% | -5.5% | 22.9% | -5.2% | -10.9% | -4.1% | -6.4% | -4.3% | -8.2% | -11.0% | -16.2% | -12.9% | -20.4% | -20.3% | -20.4% | -14.5% | -13.7% | -21.0% | -31.9% | -29.0% |
| — | +115.9% | -35.8% | +460.8% | -19.3% | -33.0% | +63.1% | +60.7% | +66.3% | +59.9% | +45.8% | +20.7% | +11.3% | -49.2% | +3.3% | +36.1% | +50.0% | +33.9% | -332.2% | -92.7% | -90.8% | |
| ROIC | 12.3% | 4.5% | -9.8% | 51.3% | -9.4% | -22.2% | -6.6% | -10.3% | -8.6% | -107.6% | — | — | — | — | — | — | — | -246.8% | — | — | -150.6% |
| — | +120.5% | -48.6% | +599.2% | -9.0% | +79.3% | — | — | — | — | — | — | — | — | — | — | — | -180.9% | — | — | -140.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.31 | 1.15 | 1.31 | 1.18 | 3.01 | 2.86 | 2.06 | 1.98 | 1.80 | 0.72 | 0.57 | 0.47 | 0.32 | 0.27 | 0.66 | 0.37 | 0.63 | 0.46 | 1.06 | — | — |
| — | -59.9% | -36.1% | -40.3% | +67.4% | +295.7% | +260.5% | +320.6% | +459.6% | +166.2% | -14.1% | +27.9% | -49.2% | -40.4% | -37.3% | — | — | -94.3% | -42.7% | — | — | |
| Debt / EBITDA | 8.53 | 17.78 | — | 2.13 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.14 | 3.63 | 3.14 | 3.54 | 3.77 | 4.08 | 4.25 | 4.36 | 5.08 | 3.77 | 3.10 | 4.29 | 5.11 | 6.88 | 4.29 | 7.21 | 7.57 | 8.85 | 6.25 | 5.05 | 4.15 |
| — | -11.1% | -26.3% | -18.7% | -25.9% | +8.2% | +37.4% | +1.6% | -0.4% | -45.2% | -27.9% | -40.4% | -32.6% | -22.2% | -31.3% | +42.8% | +82.4% | -4.3% | -12.6% | -48.8% | -71.8% | |
| Quick Ratio | 2.70 | 3.16 | 2.70 | 3.10 | 3.16 | 3.62 | 3.81 | 3.73 | 4.12 | 3.02 | 2.50 | 3.67 | 4.49 | 6.27 | 3.78 | 6.69 | 7.19 | 8.58 | 6.07 | 5.03 | 4.13 |
| — | -12.6% | -29.2% | -16.7% | -23.3% | +19.8% | +52.1% | +1.5% | -8.2% | -51.8% | -33.8% | -45.1% | -37.5% | -27.0% | -37.7% | +33.0% | +74.1% | -7.2% | -15.1% | -49.0% | -72.0% | |
| Interest Coverage | 1.54 | 2.86 | -4.41 | 20.18 | -2.74 | -7.32 | -2.13 | -3.54 | -3.01 | -8.51 | -10.77 | -18.15 | -15.60 | -22.57 | -20.64 | -23.15 | -17.41 | -15.13 | -47.95 | -84.70 | -57.19 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying APLS stock.
Apellis Pharmaceuticals, Inc.'s current P/E is 227.9x. The average P/E over the last 2 quarters is 35.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Apellis Pharmaceuticals, Inc.'s current operating margin is 5.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Apellis Pharmaceuticals, Inc.'s business trajectory between earnings reports.